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Abstract
Background: The inverse relationship between GLUT4 and RBP4 expression is known to play a role in the pathogenesis of
type 2 diabetes. Elevated levels of RBP4 were shown to cause insulin resistance in muscles and liver. Identification of STRA6
as a cell surface receptor for RBP4 provides further link in this axis and hence we analyzed SNPs in these three genes for
association with type 2 diabetes in a South Indian population.
Methodology/Principal Findings: Selected SNPs in the three genes were analyzed in a total of 2002 individuals belonging
to Dravidian ethnicity, South India, by Tetra Primer ARMS PCR or RFLP PCR. Allele frequencies and genotype distribution
were calculated in cases and controls and were analyzed for association by Chi-squared test and Logistic regression.
Haplotype analysis was carried out for each gene by including all the markers in a single block. We observed a significant
association of three SNPs, rs974456, rs736118, and rs4886578 in STRA6 with type 2 diabetes (P=0.001, OR 0.79[0.69–0.91],
P=0.003, OR 0.81[0.71–0.93], and P=0.001, OR 0.74[0.62–0.89] respectively). None of the SNPs in RBP4 and GLUT4 showed
any association with type 2 diabetes. Haplotype analysis revealed that two common haplotypes H1 (111, P=0.001, OR
1.23[1.08–1.40]) and H2 (222, P=0.002 OR 0.73[0.59–0.89]) in STRA6, H6 (2121, P=0.006, OR 1.69[1.51–2.48]) in RBP4 and H4
(2121, P=0.01 OR 1.41[1.07–1.85]) in GLUT4 were associated with type 2 diabetes.
Conclusion: SNPs in STRA6, gene coding the cell surface receptor for RBP4, were significantly associated with type 2
diabetes and further genetic and functional studies are required to understand and ascertain its role in the manifestation of
type 2 diabetes.
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Introduction
Type 2 diabetes is primarily characterized by insulin resistance,
relative insulin deficiency and fasting hyperglycemia [1]. Adipo-
cytes, muscle tissue and liver are the main insulin responsive sites in
the body. Adipocytes and muscles contain an insulin sensitive
glucose transporter, GLUT4, and are the major glucose disposal
sites in response to insulin, whereas insulin inhibits the process of
endogenous glucose production by liver. This concerted action of
insulin on adipocytes, muscles and liver helps in maintaining blood
glucose homeostasis [1,2]. It has been reported that there is an
adipocyte specific downregulation of GLUT4 in type 2 diabetes.
This decrease in GLUT4 expression is concomitant with an
increased expression of retinol binding protein 4 (RBP4) [3,4].
RBP4, expressed in adipocytes and liver, is an adipokine involved in
the transport of vitamin A/retinol. Apart from its role as a retinol
transporter, RBP4 has also been implicated in causing insulin
resistance in muscle and liver [3]. Additionally several studies in
various populations have reported elevated levels of RBP4 in type 2
diabetes and related metabolic parameters [5–7]. It was shown that
RBP4 modulates the activity of phosphoenolpyruvatecarboxykinase
(PEPCK) in liver subsequently altering gluconeogenesis [3]. In
muscles, RBP4 alters the activation of Phophoinositide-3-kinase
(PI3K) in response to insulin thus decreasing insulin stimulated
glucose uptake into muscles [3]. The recent identification of
Stimulated by Retinoic Acid gene homolog 6 (STRA6) as the high
affinity cell surface receptor for RBP4 may give us further insight
into the mode of action of RBP4 [8]. STRA6 is a multi
transmembrane domain protein that mediates the cellular uptake
of vitamin A. In accordance with its role as the transmembrane
transporter of vitamin A, STRA6 plays a major role in embryonic
development [8,9]. Studies have shown that STRA6 is overex-
pressed in colon cancer [10]. But neither functional nor genetic
studies have been carried out to identify how STRA6 may play a
role in imparting the effect of RBP4 on muscle and liver insulin
resistance and subsequently type 2 diabetes.
Genetic studies have been carried out with respect to single
nucleotide polymorphisms (SNPs) in GLUT4 and RBP4 but with
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SNPs in RBP4 with type 2 diabetes and related parameters have
been done in many populations, detailed studies of SNPs in
GLUT4 with type 2 diabetes is lacking. SNPs in both RBP4 and
GLUT4 have not been analyzed in Indian population for their
association with type 2 diabetes. With respect to GLUT4, a study
in Welsh population identified a silent polymorphism (Asn130) in
exon-4 present in diabetic subjects. They also identified a
Val383Ile mutation present in 3 out of 160 type 2 diabetes
subjects but in none of the control subjects. But further analysis in
British population failed to confirm any association of these
mutations with type 2 diabetes [15–16]. Other studies in GLUT4
include RFLP studies with KpnI enzyme in Italian, Caucasians,
Chinese, and Asian Indians, American black and Japanese
population [17–18]. These studies failed to establish an association
between the KpnI allele and type 2 diabetes. None of these studies
focused on SNPs present in the promoter and coding region of
GLUT4. Recent studies in other populations have identified
common variants and haplotypes in RBP4 to be associated with
type 2 diabetes [11,13]. Other studies have also identified SNPs in
RBP4 to be associated with altered serum lipid levels (12,14).
Interestingly, none of these studies looked at polymorphisms in
STRA6; the only identified high affinity receptor for RBP4.
The triad of GLUT4-RBP4-STRA6 may play an important role in
the pathogenesis of type 2 diabetes, wherein the adipocyte specific
down regulation of GLUT4 leads to an increased expression of
RBP4 and this increase in RBP4 expression leads to insulin
resistance via STRA6. In this study, SNPs in GLUT4, RBP4 and
STRA6 wereanalyzed forassociation with type2 diabetes ina South
Indian population. We report for the first time that genetic variants
in STRA6 are significantly associated with type 2 diabetes.
Results
Characteristics of the study population
The study was conducted by using DNA isolated from blood
samples of 2002 unrelated individuals (1002 cases with type 2
diabetes and 1000 normoglycemic control subjects) belonging to
Dravidian ethnicity from Kerala, South India. Diabetes related
clinical and biochemical parameters were collected for all the case
samples whereas fasting blood glucose, BMI and blood pressure
were documented for control samples. Clinical and biochemical
features of the study population are summarized in Table 1.
Test for Hardy-Weinberg equilibrium and LD analysis
Test for Hardy-Weinberg equilibrium suggested that the
genotypes for all the SNPs except rs351224 (STRA6) were in
Hardy-Weinberg proportions and there was no deviation from
Hardy-Weinberg equilibrium. rs351224 was subsequently omitted
from further analysis. dbSNP ID, Minor allele frequency (MAF)
and HWE P value for all the selected SNPs are summarized in
Table 2. LD analysis using Haploview revealed that the 2 SNPs in
STRA6, rs736118 and rs4886578 spanned one LD block
(D’=0.95), rs974456 was not in LD with the two SNPs and
rs351224 was omitted from the analysis due to deviation from
HWE. Kovacs et al have previously defined the LD pattern for
RBP4 for Caucasian population [12]. In our population also we
found a similar LD pattern with SNPs rs3758539, rs36014035 and
rs34571439 spanning one LD block. rs3758538 was not in LD
with any of the above SNPs. In case of GLUT4, the 4 SNPs
spanned two different LD blocks with SNPs rs2654185 and rs5412
in one LD block and SNPs rs5418 and rs5435 in the second LD
block.
Association analysis of genetic variants in GLUT4, RBP4
and STRA6 with type 2 diabetes
All the three SNPs in STRA6 viz. rs974456, rs736118 and
rs4886578 were significantly associated with type 2 diabetes
(P=0.001, OR 0.79[0.69–0.91], P=0.003, OR 0.81[0.71–0.93],
and P=0.001 OR 0.74[0.62–0.89] respectively). Significant P
values were also obtained in the additive model analysis after
adjustment for age, sex and BMI. The associations remain
statistically significant even after correction for multiple testing
by Bonferroni correction (612, P value 0.012, 0.036, and 0.012
respectively). As revealed by ODD’s Ratio (OR), all three SNPs in
STRA6 tend to be associated with a decreased susceptibility for
type 2 diabetes. None of the selected SNPs in GLUT4 or RBP4
showed any significant association with type 2 diabetes. A silent
polymorphism in GLUT4, rs5435, showed a slight trend towards
association (P=0.05). Results of association analysis are summa-
rized in Table 3.
Haplotype analysis of SNPs in GLUT4, RBP4 and STRA6
In case of STRA6, rs351224 was not included in the haplotype
analysis because of significant deviation from Hardy-Weinberg
proportions (Table 2). Therefore, only three SNPs in the order
rs974456, rs736118 and rs4886578 were used as a single block.
Five common haplotypes in STRA6 with a frequency .5%
accounted for 97% of the observed haplotypes in case subjects.
Analysis of these haplotypes in cases and controls revealed that the
haplotype H1 (GGC, 111) and H2 (AAT, 222) were significantly
associated with type 2 diabetes (P=0.001 and P=0.002
respectively) even after correction for multiple testing (P=0.005
and P=0.01) (Table 4). The haplotype H1 (GGC) had a higher
frequency in patients (61.8%) than in controls (56.9%), whereas
the haplotype H2 (AAT) was observed more in controls (12.5%)
than in cases (9.4%) indicating that the minor alleles (A,A and T)
of rs736118, rs4886578 and rs974456 are protective against type 2
diabetes. Haplotype analysis of SNPs in RBP4 revealed that six
common haplotypes with a frequency .3.5% in type 2 diabetic
patients accounted for 90% of the observed haplotypes. A case-
control analysis of these haplotypes showed that the haplotype H6
(2121, CGGT) in the order rs3758538, rs3758539, rs36014035
and rs34571439 is significantly associated (P=0.006) with type 2
diabetes (Table 5). This association remains significant even after
correction for multiple testing (P=0.036). When we omitted
rs3758538 from the haplotype analysis due to low minor allele
frequency, we found that the haplotype (121) was significantly
associated with type 2 diabetes with a P=0.002 (data not shown).
We also analyzed the haplotypes in GLUT4 for association with
type 2 diabetes. 87.7% of the total haplotypes were constituted by
Table 1. Clinical Characterization of the study population.
Subjects with
type 2 diabetes
Subjects without
type 2 diabetes
Number of subjects 1002 1000
Sex (Male/Female) 584/418 470/530
Age (Years) 55.7610.2 51.07610.2
Age of onset of diabetes (years) 45.0869.04 -
BMI (Kg/m
2)2 5 . 0 5 63.4 23.0963.9
Fasting Blood Glucose (mmol/L) 8.6763.4 4.960.58
HBA1C (%) 8.361.8 -
Data represented as mean6SD.
doi:10.1371/journal.pone.0011444.t001
STRA6 Associates with Diabetes
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Case-control analysis revealed that the haplotype H4 (2121,
AGGG) defined by SNPs rs2654185, rs5412, rs5418 and rs5435 is
marginally associated with type 2 diabetes after correction for
multiple testing (P/P*=0.01/0.04). Results of haplotype analysis
with SNPs in GLUT4 are summarized in Table 6.
Recent studies in other populations have reported a significant
association of SNPs in RBP4 with serum lipid levels [12–14]. We
also analyzed whether the promoter SNPs in RBP4 (rs3758538
and rs3758539) are associated with diabetes related phenotype in
our population. We did not observe a significant association of
these SNPs with serum lipid levels or with other analyzed traits
(data not shown). Analysis of SNPs in STRA6 also did not reveal
any significant association with type 2 diabetes related phenotypes
(data not shown). We also did not find any evidence of
multiplicative gene-gene interaction in modulating BMI, fasting
blood glucose, HBA1C and age of onset of diabetes though a
higher proportion of individuals with diabetes had higher number
of risk alleles (Fig. 1). Percentage prevalence of diabetes increased
with increase in number of risk alleles when analyzed with sentinel
SNPs in STRA6 (rs736118), RBP4 (rs3758539) and GLUT4
(rs5435).
Discussion
In this study, we used a case-control approach for analyzing
SNPs in three candidate genes viz. GLUT4, RBP4 and STRA6 for
association with type 2 diabetes. We provide evidence that SNPs in
STRA6 are significantly associated with type 2 diabetes. We also
identified two common haplotypes in STRA6 associated with type
2 diabetes. Furthermore, common haplotypes in GLUT4 and
RBP4 were also found to be associated with type 2 diabetes. After a
Table 2. Summary of selected SNPs.
dbSNP ID Gene Position MAF HWE P value (Controls) HWE P value (Cases)
rs974456 STRA6 Intron 7 0.27 0.18 0.54
rs351224 STRA6 Intron 7 0.43 3.5610
25 0.002
rs736118 STRA6 Exon 17 0.32 0.14 0.45
rs4886578 STRA6 Intron 18 0.14 0.074 0.9
rs3758538 RBP4 promoter 0.18 0.37 0.8
rs3758539 RBP4 promoter 0.33 0.43 0.64
rs36014035 RBP4 Intron 4 0.42 0.96 0.49
rs34571439 RBP4 39UTR 0.35 0.23 0.07
rs2654185 GLUT4 promoter 0.37 0.14 0.07
rs5412 GLUT4 promoter 0.30 0.12 0.52
rs5418 GLUT4 59UTR 0.38 0.42 0.29
rs5435 GLUT4 Exon 4 0.30 0.59 0.62
MAF – minor allele frequency in the whole study group. HWE – Hardy Weinberg Equillibrium. SNPs were selected from dbSNP, NCBI based on their position in the gene,
minor allele frequency or previous studies. Hardy Weinberg test was done using the Pearson’s goodness of fit test and a P value ,0.05 was considered to show
significant deviation of the observed genotypes from Hardy-Weinberg proportions.
doi:10.1371/journal.pone.0011444.t002
Table 3. Association analysis of selected SNPs in STRA6, RBP4 and GLUT4 with type 2 diabetes.
SNP ID Gene Allele major/minor MAF OR (95%CI) P/P* P(add)
Cases Control
rs974456 STRA6 C/T 0.25 0.30 0.79(0.69–0.91) 0.001/0.012 0.003
rs736118 STRA6 G/A 0.30 0.35 0.81(0.71–0.93) 0.003/0.036 0.01
rs4886578 STRA6 G/A 0.12 0.16 0.74(0.62–0.89) 0.001/0.012 0.0009
rs3758538 RBP4 A/C 0.19 0.18 1.06(0.9–1.2) 0.43/NS 0.63
rs3758539 RBP4 G/A 0.33 0.35 0.91(0.79–1.04) 0.18/NS 0.48
rs36014035 RBP4 T/G 0.43 0.42 1.02(0.9–1.16) 0.71/NS 0.18
rs34571439 RBP4 T/G 0.35 0.36 0.93(0.82–1.07) 0.35/NS 0.63
rs2654185 GLUT4 C/A 0.37 0.36 1.01(0.89–1.15) 0.83/NS 0.5
rs5412 GLUT4 G/A 0.29 0.31 0.88(0.76–1.01) 0.07/NS 0.05
rs5418 GLUT4 A/G 0.37 0.40 0.89(0.77–1.02) 0.09/NS 0.25
rs5435 GLUT4 G/A 0.29 0.32 0.87(0.76–1.00) 0.05/NS 0.1
MAF- minor allele frequency, OR- ODD’s ratio. P- P value calculated by Chi Squared test for difference in allele frequency between cases and controls. * - P value after
Bonferroni correction, P(add) – P value obtained by logistic regression after adjustment for age, sex and BMI using an additive model. P values showing significant
association have been indicated in bold. NS- Not significant.
doi:10.1371/journal.pone.0011444.t003
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control samples, we found that the three SNPs in STRA6,
rs736118 (P=0.003), rs4886578 (P=0.001) and rs974456
(P=0.001) were significantly associated with type 2 diabetes.
rs736118 is a G.A polymorphism leading to a Met to Ile change
in the C-terminal end of STRA6. Though Met and Ile are
hydrophobic amino acids, evidence from literature suggests that
such changes can alter the trafficking and cell surface expression of
proteins. For example, a V302M mutation in the cytoplasmic G
loop of Kir6.2 (KCNJ2) led to a loss of coassembly with the wild
type protein thereby affecting protein trafficking to the cell surface
[20]. Alternatively, it was also shown that this mutation can
modulate the potassium ion conductance by Kir6.2 [21].
rs4886578 (G.A), is an exon-intron boundary polymorphism
whereas rs974456 (C.T) is present in intron 7. It has been shown
that SNPs present in the non-coding region can modulate gene
expression and SNPs present in exon-intron boundary can alter
splice forms [22]. Thus, both these variations can lead to
differential expression of the protein. Subsequent haplotype
analysis revealed two haplotypes (H1-CGG and H2- TAA, in
the order rs974456, rs736118 and rs4886578) to be significantly
associated with type 2 diabetes (P=0.001 and P=0.002).
Haplotype H1 was present more in type 2 diabetic patients
(61.8%) than normoglycemic controls (56.8%) whereas the
haplotype H2 was present more in normoglycemic controls
(12%) than in cases (9.4%). This indicates that the haplotype H2
which is composed of the minor alleles in the 3 SNPs decreases the
susceptibility to type 2 diabetes. These findings support the
hypothesis that STRA6 acts as a putative link between RBP4 and
its effect on muscle, liver and whole body insulin resistance.
Additionally it was reported that Wnt-1 and retinoic acid
synergistically induce the expression of STRA6 [10]. It is
interesting to note that TCF4, a transcription factor, coded by
TCF7L2, the most strongly associated and replicated type 2
diabetes susceptibility loci, is an integral part of Wnt-1 signaling
[23–29]. TCF4 is known to interact with b-catenin and induces
several wnt-1 signalling target genes, and it is possible that TCF4
also induces the expression of STRA6. The role of STRA6 in type
2 diabetes and its regulation by TCF4 are currently under
investigation in our laboratory.
We also analyzed SNPs in RBP4 and GLUT4 for association
with type 2 diabetes and related parameters. SNPs in RBP4 have
been previously reported to be associated with type 2 diabetes in
Mongolian population [11]. They identified a functional variant
(rs3758539) in the promoter of RBP4 associated with type 2
diabetes. Another study which analyzed SNPs in the RBP4 for
association with type 2 diabetes identified a common haplotype
associated with type 2 diabetes but failed to observe any single
SNP association [12]. We also did not observe any significant
association of SNPs in RBP4 but our haplotype analysis revealed
that a common haplotype (H6 – CGGT in the order rs3758538,
rs3758539, rs36014035 and rs34571439) is significantly associated
with type 2 diabetes (P=0.004). Kovacs et al. identified significant
association of the common haplotype AGGTGC (defined by the
order rs3758538, rs3758539, rs10882283, c.248+44T.C,
rs1226584 and rs10882273) with type 2 diabetes [12]. They also
reported that the SNP rs1226584 is in complete LD with
rs34571439, and rs10882273 is in complete LD with
rs34571439. Thus, the haplotype association we identified is
comparable to the one reported in the above study except for
rs3758538. This may be due to the lower minor allele frequency of
rs3758538 and comparably similar frequencies in cases and
controls. Other genetic studies with SNPs in RBP4 have reported
association with serum lipid parameters but in our study we failed
to observe any significant association of the promoter polymor-
phisms with serum lipid levels or with other diabetes related
Table 4. Haplotype analysis of selected SNPs in STRA6.
Haplotypes Type 2 diabetes patients (%) Non diabetic controls (%) OR (95%CI) P/P* values
H1 111 61.8 56.9 1.23(1.08–1.40) 0.001/0.005
H2 222 9.46 12.5 0.73(0.59–0.89) 0.002/0.01
H3 121 9.67 9.43 1.03(0.83–1.27) 0.76/NS
H4 221 9.06 9.78 0.92(0.74–1.14) 0.45/NS
H5 211 7.06 7.89 0.88(0.70–1.12) 0.33/NS
Haplotype frequencies were compared using Chi squared test. Haplotypes are defined by selected SNPs in STRA6 in the following order – rs974456, rs736118 and
rs4886578. rs351224 was not included in the haplotype analysis. * P values after Bonferroni correction. NS- not significant, 1-major allele, 2- minor allele.
doi:10.1371/journal.pone.0011444.t004
Table 5. Haplotype analysis of selected SNPs in RBP4.
Haplotypes Type 2 diabetes patients (%) Non diabetic controls (%) OR (95%CI) P/P* values
H1 1111 48.6 48.3 1.01 (0.89–1.16) 0.77/NS
H2 1222 20.6 22.2 0.91 (0.78–1.07) 0.27/NS
H3 2222 7.3 7.4 1.0 (0.78–1.28) 0.99/NS
H4 2111 5.0 5.5 0.9 (0.68–1.21) 0.51/NS
H5 1121 4.6 3.5 1.31 (0.94–1.81) 0.1/NS
H6 2121 3.8 2.2 1.69 (1.51–2.48) 0.006/0.036
Haplotype frequencies were compared using Chi squared test. Haplotypes are defined by selected SNPs in RBP4 in the following order – rs3758538, rs3758539,
rs36014035 and rs34571439. * P values after Bonferroni correction. NS- not significant, 1-major allele, 2- minor allele.
doi:10.1371/journal.pone.0011444.t005
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retinopathy with enhanced expression in cases with proliferative
diabetic retinopathy when compared to non–proliferative diabetic
retinopathy or no retinopathy [30]. However, in this study, we did
not observe any significant association of SNPs in RBP4 and
STRA6 with diabetic retinopathy in a case control analysis using
155 samples with diabetic retinopathy and 150 samples with type 2
diabetes for more than 12 years with no symptoms of diabetic
retinopathy.
Although GLUT4 is a strong candidate gene for diabetes related
studies, we did not find any evidence of individual SNPs in GLUT4
associated with type 2 diabetes in our population. Haplotype
analysis with selected SNPs revealed a common haplotype 2121
defined by the order rs2654185, rs5412, rs5418 and rs5435
marginally associated with type 2 diabetes. We also found that the
SNP rs5435 showed an increasing trend towards association with
considerable difference in minor allele frequency in cases and
controls. Probably this SNP in GLUT4 may increase the
susceptibility to type 2 diabetes in combination with other SNPs.
It should be noted that the sample size used in this analysis is
suitable for stronger effects as found in STRA6 but smaller effects
like those observed in GLUT4 (rs5435) may be missed and analysis
of a larger sample size may confirm such effects. Our gene-gene
interaction data reveals that when the sentinel SNPs in STRA6,
RBP4 and GLUT4 are combined together they increase the
prevalence of type 2 diabetes with increase in the number of risk
alleles (Figure 1B). This indicates that the three genes may play a
combined role in increasing the susceptibility of type 2 diabetes.
But this increase in number of risk alleles had no effect on BMI
(Figure 1C), fasting blood glucose (Figure 1D) or HBA1c
(Figure 1E) indicating that the increase in the susceptibility of
type 2 diabetes is modulated through some other pathway most
probably by affecting the measure of insulin resistance.
Recent Genome Wide Association Studies (GWAS) in different
populations have identified various type 2 susceptibility genes
[31–34]. But most of these studies have been done in Western
population and only few GWAS studies have been carried out in
Asian population, notably in Japanese and Han Chinese
population [35–36]. Most of the type 2 susceptibility genes
identified by GWAS in Western population play a role in insulin
secretion which correlates well with the type 2 diabetes phenotype
in that population. GWAS study in Japanese population also led to
the identification of type 2 diabetes susceptibility genes similar to
that found in Western population but with greater effect size and
explained variance [35]. GWAS study in Japanese population also
identified KCNQ1 as a diabetes susceptibility loci which was further
confirmed in other population [37–38]. Similar GWAS studies in
Han Chinese led to the confirmation of the common type 2
succeptibility genes observed in Western and Japanese population
with the addition of two more novel type 2 diabetes susceptibility
loci. The study identified PTPRD and Serine Racemase (SRR)a s
novel type 2 diabetes susceptibility genes not observed in Japanese
and Western population [36].
GWAS data for type 2 diabetes in South Indian population is
still not available. India has the highest number of cases with type
2 diabetes and is referred as the diabetic capital of the world with
58.4 million people with type 2 diabetes. Indian population differs
from other population in certain unique biochemical and clinical
parameters like increased insulin resistance, higher adiposity,
lower adiponectin levels and higher levels of sensitive C-reactive
protein [39]. This indicates that in Indian population the adipose
tissue mass in the form of central obesity plays a crucial role in the
pathogenesis of type 2 diabetes. Similarly genetic factors also differ
in their effect on type 2 diabetes as compared to European
population. None of the GWAS study in other populations
identified STRA6 as a susceptibility loci for type 2 diabetes. Since
no data was available for South Indian population in HapMap we
compared LD pattern of the recently included Gujarati Indian
population from Houston, Texas (GIH) with Japanese (JPT), Han
Chinese (CHB) and western population (CEU) for differences in
LD pattern of the STRA6 gene. We found that the LD pattern in
GIH population was different from other populations.
In conclusion, we analyzed SNPs in three candidate genes
namely, GLUT4, RBP4 and STRA6 for association with type 2
diabetes. We provide evidence supporting a novel genetic role for
the STRA6 loci in type 2 diabetes. A significant association was
observed between two common haplotypes in STRA6 and type 2
diabetes. Additionally haplotype analysis with SNPs in RBP4 and
GLUT4 also revealed significant association of a common
haplotype in both genes with type 2 diabetes.
Materials and Methods
Ethics statement
Written informed consent forms were obtained from all the
participating subjects. The study was conducted following the
guidelines of Indian Council of Medical Research and approved
by the ethics committee at AIMS.
Case and Control samples
The study was conducted using samples from 2002 unrelated
individuals from Kerala, South India as a part of an ongoing
project, Amrita Diabetes Awareness and Welfare Study. Case
samples were collected from Endocrinology department, Amrita
Institute of Medical Sciences (AIMS), Kochi, Kerala. All samples
were collected following the guidelines of American Diabetes
Association with fasting blood glucose .120 mg/dl and/or 2-hour
plasma glucose .200 mg/dl. Case samples were collected after
detailed investigation of medical records for symptoms, use of oral
hypoglycemic agent and/or insulin, measurement of fasting blood
Table 6. Haplotype analysis of selected SNPs in GLUT4.
Haplotypes Type 2 diabetes patients Non diabetic controls Chi squared P/P* values
H1 1111 31.5 29.0 1.12 (0.96–1.30) 0.12/NS
H2 1211 24.8 26.0 0.93 (0.80–1.09) 0.41/NS
H3 2122 23.4 26.0 0.86 (0.74–1.01) 0.07/NS
H4 2121 8.0 5.8 1.41 (1.07–1.85) 0.01/0.04
Haplotype frequencies were compared using Chi squared test. Haplotypes are defined by selected SNPs in GLUT4 in the following order – rs2654185, rs5412, rs5418 and
rs5435. *- P values after Bonferroni correction. NS- not significant, 1-major allele, 2- minor allele.
doi:10.1371/journal.pone.0011444.t006
STRA6 Associates with Diabetes
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diagnosed with type 2 diabetes after the age of 60 or subjects who
were started on insulin therapy within one year of diagnosis were
excluded from the study. Subjects with type 1 diabetes, family
history of type 1 diabetes, maturity onset diabetes of the young,
monogenic forms of diabetes, or drug induced diabetes were also
excluded from the study. Samples from patients outside Kerala
and patients migrating from other parts of the country were not
included. Case reports of diabetic nephropathy, diabetic retinop-
athy and fatty liver disease as diagnosed by the physician were also
documented during collection.
Age, sex and ethnicity matched normoglycemic control subjects
were recruited in the study by public advertisement and increased
awareness by offering screening for diabetic risk factors at specially
organized medical camps. All the participants of these medical
camps were subjected to a health questionnaire for detailed
investigation of their disease status, family history, socio-economic
status, food habits, smoking and alcohol status, BMI and blood
Figure 1. Combined effect of increasing number of risk alleles from STRA6 (rs736118), RBP4 (rs3758539) and GLUT4 (rs5435). A. risk
allele distribution in subjects with and without type 2 diabetes. B. percentage prevalence of type 2 diabetes in the study population with increasing
number of risk alleles. C, D, E and F. Association analysis of BMI, fasting blood glucose, HBA1C and age at onset of diabetes with increasing number of
risk alleles.
doi:10.1371/journal.pone.0011444.g001
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a) above 40 years of age, b) no family history of diabetes, c) not
taking any oral hypoglycemic agent or insulin, d) blood glucose
levels ,110 mg/dl. Clinical characterization of the study subjects
is summarized in the Table 1.
Genotyping
Genomic DNA was isolated from peripheral blood leukocytes
by salting out procedure [40]. SNP genotyping was performed by
Tetraprimer Amplification Refractory Mutation System PCR
(Tetraprimer ARMS PCR) and Restriction Fragment Length
Polymorphism PCR (RFLP PCR) [41]. A total of 12 SNPs from
STRA6, RBP4 and GLUT4 were selected from dbSNP, NCBI,
either based on their position in the gene viz. 59 UTR, exon, exon-
intron boundary, 39UTR and minor allele frequency (MAF,
.0.05) reported in dbSNP or based on previous association
studies. All the novel SNPs were selected based on their position to
influence the expression or function of the protein. rs5435 in
GLUT4 has been previously studied in European population. In
addition, we selected three more SNPs in GLUT4 based on
position and minor allele frequency as reported in dbSNP, NCBI.
For RBP4, we selected SNPs based on previous studies in
European population whereas for STRA6, SNPs were selected
based on their reported population diversity data and position in
the gene. There is only one reported non- synonymous SNP,
rs736118, in STRA6 with population diversity data and a MAF
.0.05 in Asian population so only this SNP from the coding
region of STRA6 was included in the study. Other SNPs selected
from STRA6 include rs4886578 present in the intron-exon
boundary, rs974456 and rs351224 present in the intron. All SNPs
were genotyped by tetraprimer ARMS PCR and RFLP PCR.
Genotyping success rate was generally .96% except for rs5418 in
GLUT4 where the success rate was .87%. A summary of selected
SNPs is given in Table 2. All SNPs except rs736118 (STRA6),
rs974456 (STRA6) and rs5418 (GLUT4) were genotyped by
Tetraprimer ARMS PCR. Genotyping plates which showed
amplification in negative control (without template DNA) were
repeated. All ambiguous genotypes were also repeated in
duplicates till clear genotypes were available. Approximately
10% (n=194) samples were re-genotyped for cross validation and
the genotype success rate was .99.5%. rs736118, rs974456 and
rs5418 were genotyped by RFLP-PCR using the restriction
enzymes Nco1, Xho1 and BamH1 respectively. In case of
rs736118 (Nco1) and rs974456 (Xho1) the presence of minor
allele resulted in the lack of restriction enzyme site and hence there
was no change in the PCR amplicon after restriction digestion. So
to ensure the genotyping accuracy all samples homozygous for the
minor allele were selectively re-genotyped. Randomly selected
10% samples were genotyped for these SNPs also and the
genotyping accuracy was found to be .99.5%. All DNA
amplicons and fragments were analyzed by agarose gel electro-
phoresis and visualized by ethidium bromide staining in gel
documentation system, Biorad, USA. PCR primer designs and
reaction conditions are available on request.
Statistical analysis
Hardy Weinberg equilibrium (HWE) test was done for each
SNP by Pearson’s Goodness of fit Chi square test before further
analysis. Association analysis of each SNP with type 2 diabetes was
done by Chi-square test, for difference in allele frequency between
cases and controls. Association of SNPs with type 2 diabetes was
also confirmed by logistic regression analysis after adjustment for
age, sex and BMI. An additive model was used for logistic
regression where homozygotes for the major allele (1_1),
heterozygotes (1_2) and homozygotes for the minor allele (2_2)
were coded to a continuous numeric variable for the genotype as
0, 1 and 2 respectively. Linkage disequilibrium was estimated for
combined data of cases and controls using Haploview version 4.1.
Haplotype analysis was done by using the software SNP and
Variation Suite Ver-7 from Golden Helix, Inc. Haplotype analysis
was done by using all the markers in a gene as a single block.
Quantitative traits were analyzed for association with type 2
diabetes by ANCOVA (available at http://faculty.vassar.edu/
lowry/VassarStats.html) and multivariate regression analysis after
adjustment for age, sex and BMI. Correction for multiple testing
was done by Bonferroni’s inequality method wherever applicable
and was defined as P value (single tests) 6 number of tests.
Bonferroni correction was not done for multiple traits due to lack
of any significant association. Multiallelic analysis with sentinel
SNPs in STRA6 (rs736118), RBP4 (rs3758539) and GLUT4
(rs5435) was done by ANOVA after categorizing the participants
into groups according to the number of risk alleles they carried. All
association analysis was performed using the software SNP and
Variation Suite Ver-7 from Golden Helix, Inc.
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